Do Atypical Antipsychotics Have Antisuicidal Effects? A Hypothesis-Generating Overview
Open accessThe DOI matches its Crossref record; 95 of the 96 references it cites were found in a registry or an index.
Abstract
Modern antipsychotic drugs are employed increasingly in the treatment of mood disorders as well as psychoses, stimulating interest in their possible contributions to altering suicidal risk. Clozapine remains the only treatment with an FDA-recognized indication for reducing suicidal risk (in schizophrenia). We carried out a systematic, computerized search for reports of studies involving antipsychotic drug treatment and suicidal behaviors. A total of 19 reports provide data with preliminary support for potential suicide risk-reducing effects of olanzapine, quetiapine, ziprasidone, aripiprazole, and asenapine in addition to clozapine, and provide some support for antipsychotic drug treatment in general. These preliminary findings encourage further testing of antipsychotics for effects on suicidal behavior, making use of explicit, pre-planned assessments of suicidal behavior.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second‐generation antipsychotics may be more effective than first‐generation ones in reducing suicide risk, although few studies have examined their impact on suicidality in older patients with schizophrenia 257 .”
From Mental health care for older adults: recent advances and new directions in clinical practice and research (2022) · cites this paper as [257]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Meltzer, H. Y. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.82 · Cited by 1,393 · cited 7×
“olanzapine in suicidal patients with chronic psychotic disorders [38].”
BackgroundResultInfluentialTiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354 · cited 3×
“2009 [5] 5360 Sz National database Perphenazine Suicide OR: 1.”
BackgroundInfluentialAtypical antipsychotic drugs and the risk of sudden cardiac death
Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806994 · Cited by 1,194 · cited 2×
“Risk of mortality due to natural causes, including sudden death presumably related to cardiac dysfunction, may be increased with older neuroleptics as well as with modern atypical or second-generation antipsychotics (SGAs) [15,16].”
BackgroundTime-related predictors of suicide in major affective disorder
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.9.1189 · Cited by 1,058
(1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.4.457 · Cited by 891
Calabrese, J. R., Keck, P. E., Macfadden, W., Minkwitz, M., Ketter, T. A., Weisler, R. H., Cutler, A. J., McCoy, R., Wilson, E., Mullen, J., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.7.1351 · Cited by 883 · cited 8×
“Reduction in MADRS depression scores was greater with both doses of quetiapine than with duloxetine or placebo, and included improvements in the suicidal item-10 of the ratings, as well as in insomnia.”
BackgroundMethodInfluentialSchizophrenia and suicide: Systematic review of risk factors
Hawton, K., Sutton, L., Haw, C., Sinclair, J., & Deeks, J. J. (2005) · British Journal of Psychiatry · doi:10.1192/bjp.187.1.9 · Cited by 774 · cited 1×
“Risk of suicide appears to be greater among psychotic disorder patients who are younger, male, never married, with evidence of current or previous depression or substance abuse, as well as previous suicide attempts, and who have had relatively good premorbid functioning [8,10,11].”
BackgroundTran, P. V., Hamilton, S. H., Kuntz, A. J., Potvin, J. H., Andersen, S. W., Beasley, C. J., & Tollefson, G. D. (1997) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199710000-00010 · Cited by 715
(2000) · PubMed · Cited by 685
Siskind, D., McCartney, L., Goldschlager, R., & Kisely, S. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.177261 · Cited by 601
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.2.183 · Cited by 436 · cited 2×
“a review of over 400 schizophrenia patients, Meltzer and Okayli [35] suggested that clozapine might reduce suicidal risk more than other antipsychotics.”
BackgroundYoung, A. H., McElroy, S. L., Bauer, M., Philips, N., Chang, W., Olausson, B., Paulsson, B., Brecher, M., & EMBOLDEN I (Trial 001) Investigators (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04995gre · Cited by 390
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Self-citationSuicide risk in schizophrenia: learning from the past to change the future
Pompili, M., Amador, X. F., Girardi, P., Harkavy-Friedman, J., Harrow, M., Kaplan, K., Krausz, M., Lester, D., Meltzer, H. Y., Modestin, J., et al. (2007) · Annals of General Psychiatry · doi:10.1186/1744-859x-6-10 · Cited by 358
Self-citationZhang, J.-P., Gallego, J. A., Robinson, D. G., Malhotra, A. K., Kane, J. M., & Correll, C. U. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001277 · Cited by 336
McElroy, S. L., Weisler, R. H., Chang, W., Olausson, B., Paulsson, B., Brecher, M., Agambaram, V., Merideth, C., Nordenhem, A., Young, A. H., et al. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04942gre · Cited by 328
Mortality in Current and Former Users of Clozapine
Walker, A. M., Lanza, L. L., Arellano, F., & Rothman, K. J. (1997) · Epidemiology · doi:10.1097/00001648-199710000-00010 · Cited by 328 · cited 1×
“discontinued long-term treatment with clozapine [36].”
Balázs, J., Benazzi, F., Rihmer, Z., Rihmer, A., Akiskal, K. K., & Akiskal, H. S. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.12.049 · Cited by 303
Suicidal risk during treatment with clozapine: a meta-analysis
Hennen, J., & Baldessarini, R. J. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.05.015 · Cited by 287 · cited 2×
“An exception is clozapine, a highly effective though potentially toxic antipsychotic drug with established antisuicidal effects in psychotic disorder patients and some preliminary suggestions of such benefits in mood disorder patients as well [12,38,41,90,91].”
BackgroundSelf-citationClinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment
Viguera, A. C. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830130055011 · Cited by 246 · cited 1×
“However, it is not clear whether these changes represented a return to an untreated state or an adverse effect of drug discontinuation itself as an iatrogenic stressor [55].”
BackgroundMortality in Current and Former Users of Clozapine
Walker, A. M., Lanza, L. L., Arellano, F., & Rothman, K. J. (1997) · Epidemiology · doi:10.1097/00001648-199711000-00014 · Cited by 239
Suppes, T., Vieta, E., Liu, S., Brecher, M., Paulsson, B., & Trial 127 Investigators (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08020189 · Cited by 230 · cited 2×
“2009 [65] 1953 BD-I RCT Placebo Depression —— Quetiapine + lithium or + divalproex reduced new depression 67% Tiihonen et al.”
BackgroundAntipsychotic treatment and mortality in schizophrenia.
Torniainen, M., Mittendorfer-Rutz, E., Tanskanen, A., Bjorkenstam, C., Suvisaari, J., Alexanderson, K., & Tiihonen, J. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu164 · Cited by 208
Prevalence, chronicity, burden and borders of bipolar disorder
Fagiolini, A., Forgione, R., Maccari, M., Cuomo, A., Morana, B., Dell'Osso, M. C., Pellegrini, F., & Rossi, A. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.02.001 · Cited by 194
El-Khalili, N., Joyce, M., Atkinson, S., Buynak, R. J., Datto, C., Lindgren, P., & Eriksson, H. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710000015 · Cited by 185
Simon, N. M., Zalta, A. K., Otto, M. W., Ostacher, M. J., Fischmann, D., Chow, C. W., Thompson, E. H., Stevens, J. C., Demopulos, C. M., Nierenberg, A. A., et al. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.08.004 · Cited by 183
Depression, Suicide, and Suicide Prevention in Schizophrenia
Fenton, W. S. (2000) · Suicide and Life-Threatening Behavior · doi:10.1111/j.1943-278x.2000.tb01063.x · Cited by 175 · cited 1×
“Risk of suicide appears to be greater among psychotic disorder patients who are younger, male, never married, with evidence of current or previous depression or substance abuse, as well as previous suicide attempts, and who have had relatively good premorbid functioning [8,10,11].”
BackgroundMcGirr, A., Renaud, J., Seguin, M., Alda, M., Benkelfat, C., Lesage, A., & Turecki, G. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.06.016 · Cited by 174
Keck, P. E., Strakowski, S. M., & McElroy, S. L. (2000) · PubMed · Cited by 140
Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study
Altamura, A. C., Bassetti, R., Bignotti, S., Pioli, R., & Mundo, E. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00164-0 · Cited by 137
Cutler, A. J., Montgomery, S. A., Feifel, D., Lazarus, A., Åström, M., & Brecher, M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04592 · Cited by 137
Detke, H. C., DelBello, M. P., Landry, J., & Usher, R. W. (2015) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.12.012 · Cited by 135 · cited 1×
“This combination has shown particular efficacy in bipolar depression, and is effective in bipolar mixed states as well as in juveniles with suspected bipolar depression [3,52,53].”
BackgroundSuicide attempts in bipolar disorders: comprehensive review of 101 reports
Tondo, L., Pompili, M., Forte, A., & Baldessarini, R. J. (2016) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12517 · Cited by 132
Self-citationKhan, A., Khan, S. R., Leventhal, R. M., & Brown, W. A. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1449 · Cited by 130 · cited 1×
“A meta-analysis of an FDA database of controlled trials found that rates of suicide and attempts (as incidentally reported adverse outcomes) did not differ significantly between drug- and placebo-treated patients among drugs that included olanzapine, risperidone, and quetiapine [51].”
BackgroundImpact of Atypical Antipsychotics on Quality of Life in Patients with Schizophrenia
Awad, A. G., & Voruganti, L. N. P. (2004) · CNS Drugs · doi:10.2165/00023210-200418130-00004 · Cited by 125 · cited 1×
“Reported studies involving ziprasidone appear to be limited to indirect assessments related to suicidal risk, notably by documenting beneficial effects on known risk factors for suicide in persons diagnosed with schizophrenia, including anxiety, depressive symptoms, or impulsive behaviors [57,75], as well perhaps as i…”
BackgroundTreatment of Suicidality in Schizophrenia
Meltzer, H. Y. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb05797.x · Cited by 124
A critical review of akathisia, and its possible association with suicidal behaviour
Hansen, L. (2001) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.325 · Cited by 119
Increased suicide attempt rate among patients interrupting use of atypical antipsychotics
Herings, R. M. C., & Erkens, J. A. (2003) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.837 · Cited by 119 · cited 1×
“Finally, it has been reported that discontinuing antipsychotic drug treatment, including olanzapine or risperidone, can be followed by an increase in suicide attempt rates [54].”
BackgroundAssociation of Recurrent Suicidal Ideation With Nonremission From Acute Mixed Mania
Goldberg, J. F., Garno, J. L., Leon, A. C., Kocsis, J. H., & Portera, L. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.12.1753 · Cited by 114
Suicide in schizophrenia: risk factors and clozapine treatment.
Meltzer, H. Y. (1998) · PubMed · Cited by 105
Bauer, M., El-Khalili, N., Datto, C. J., Szamosi, J., & Eriksson, H. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.08.032 · Cited by 100
Jann, M. W. (2014) · PubMed · Cited by 97
SWANN, A. C., STEINBERG, J. L., LIJFFIJT, M., & MOELLER, G. F. (2009) · World Psychiatry · doi:10.1002/j.2051-5545.2009.tb00245.x · Cited by 95
The clinical challenges of akathisia
Lohr, J. B., Eidt, C. A., Abdulrazzaq Alfaraj, A., & Soliman, M. A. (2015) · CNS Spectrums · doi:10.1017/s1092852915000838 · Cited by 94
Bortnick, B., El-Khalili, N., Banov, M. D., Adson, D. E., Datto, C. J., Raines, S. R., Earley, W. R., & Eriksson, H. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.06.031 · Cited by 93 · cited 1×
“In yet another trial with 310 depressed subjects, quetiapine (150 mg/day) was more effective than the placebo in treating depressive symptoms, showed some benefit within one day, and again yielded reduced scores on suicidal item-10 of the MADRS depression rating scale [69].”
BackgroundHaukka, J., Tiihonen, J., Härkänen, T., & Lönnqvist, J. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1579 · Cited by 84 · cited 2×
“2008 [4] 394 Sz National database No treatment Suicide attempt HR: 1.”
BackgroundClozapine Diminishes Suicidal Behavior: A Retrospective Evaluation of Clinical Records
Modestin, J., Pian, D. D., & Agarwalla, P. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0418 · Cited by 79 · cited 2×
“[43], in a retrospective analysis of patients treated with clozapine, found significantly less suicidal behavior among schizophrenia patients treated with clozapine vs.”
BackgroundBipolar mixed episodes and antidepressants: a cohort study of bipolar I disorder patients
Valentí, M., Pacchiarotti, I., Rosa, A. R., Bonnín, C. M., Popovic, D., Nivoli, A. M. A., Murru, A., Grande, Í., Colom, F., & Vieta, E. (2011) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00908.x · Cited by 78
Ringbäck Weitoft, G., Berglund, M., Lindström, E. A., Nilsson, M., Salmi, P., & Rosén, M. (2014) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3567 · Cited by 77
Montout, C., Casadebaig, F., Lagnaoui, R., Verdoux, H., Philippe, A., Bégaud, B., & Moore, N. D. (2002) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00325-5 · Cited by 77 · cited 1×
“Risk of mortality due to natural causes, including sudden death presumably related to cardiac dysfunction, may be increased with older neuroleptics as well as with modern atypical or second-generation antipsychotics (SGAs) [15,16].”
BackgroundSpivak, B., Shabash, E., Sheitman, B., Weizman, A., & Mester, R. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0703 · Cited by 73
Suicidal Behavior in Mood Disorders: Response to Pharmacological Treatment
Tondo, L., & Baldessarini, R. J. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0715-0 · Cited by 71 · cited 2×
“A clinically important insight arising over the past two decades is that suicidal behavior may be amenable to medicinal treatments, including lithium, perhaps less so with mood-stabilizing anticonvulsants, and possibly with antidepressants in adults more than juveniles [1,2].”
BackgroundSelf-citationSchneidman, E. S. (1999) · Cited by 67
Benazzi, F., Berk, M., Frye, M. A., Wang, W., Barraco, A., & Tohen, M. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04772gre · Cited by 65 · cited 1×
“This combination has shown particular efficacy in bipolar depression, and is effective in bipolar mixed states as well as in juveniles with suspected bipolar depression [3,52,53].”
BackgroundFindling, R. L., Çavuş, I., Pappadopulos, E., Vanderburg, D. G., Schwartz, J. H., Gundapaneni, B. K., & DelBello, M. P. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0068 · Cited by 63
McIntyre, R. S., Tohen, M., Berk, M., Zhao, J., & Weiller, E. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.04.025 · Cited by 60 · cited 1×
“Other studies also support the value of asenapine in treating both manic and depressive features of bipolar disorder, especially in mixed states [87,88].”
ResultBarak, Y., Mirecki, I., Knobler, H. Y., Natan, Z., & Aizenberg, D. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1801-2 · Cited by 60 · cited 1×
“2004 [50] 756 Sz Case-control chart review Risperidone or Neuroleptics Suicide attempt OR: 0.”
BackgroundVieta, E., Grunze, H., Azorin, J.-M., & Fagiolini, A. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.12.031 · Cited by 57 · cited 1×
“Furthermore, across the complex range of bipolar mixed states, common clinical elements include depressed mood, sleeplessness, pessimism, agitation, anxiety, irritability, or anger, in states of very unpleasant and distressing dysphoria—all of which can contribute to the risk of suicide [24,34].”
BackgroundTreatment of bipolar disorder: Review of evidence regarding quetiapine and lithium
Ketter, T. A., Miller, S., Dell’Osso, B. M., & Wang, P. W. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.11.002 · Cited by 55 · cited 1×
“Up to the year 2000, more than 10,000 patient-years of testing were represented in controlled trials of quetiapine [61].”
BackgroundFornaro, M., Stubbs, B., De Berardis, D., Perna, G., Valchera, A., Veronese, N., Solmi, M., & Ganança, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17020241 · Cited by 53
Aripiprazole monotherapy in the treatment of bipolar disorder: A meta-analysis
Fountoulakis, K. N., Vieta, E., & Schmidt, F. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.10.018 · Cited by 52 · cited 1×
“might be modified by this agent, including improved social interactions and general quality of life, in addition to antipsychotic and calming effects [57,81].”
BackgroundAzorin, J., Sapin, C., & Weiller, E. (2012) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.07.013 · Cited by 51 · cited 2×
“2013 [87] 295 BD-I Pooled RCTs Olanzapine Depression —— Asenapine effective vs.”
BackgroundResultImpact of psychotropic drugs on suicide and suicidal behaviors
Yerevanian, B. I., & Choi, Y. M. (2013) · Bipolar Disorders · doi:10.1111/bdi.12098 · Cited by 51 · cited 1×
“An exception is clozapine, a highly effective though potentially toxic antipsychotic drug with established antisuicidal effects in psychotic disorder patients and some preliminary suggestions of such benefits in mood disorder patients as well [12,38,41,90,91].”
BackgroundWagstaff, A. J., & Perry, C. M. (2003) · CNS Drugs · doi:10.2165/00023210-200317040-00004 · Cited by 48 · cited 1×
“In another randomized, rater-blinded study, clozapine was again associated significantly with 22%–25% fewer suicide-related behavioral outcomes than olanzapine among schizophrenia or schizoaffective disorder patients with recent suicide attempts [40].”
BackgroundMedication and suicide risk in schizophrenia: A nested case–control study
Reutfors, J., Bahmanyar, S., Jönsson, E. G., Brandt, L., Bodén, R., Ekbom, A., & Ösby, U. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.09.001 · Cited by 45
Kasper, S. F. (2004) · Depression and Anxiety · doi:10.1002/da.20017 · Cited by 42
Formulary decisions and health economics.
Glazer, W. M. (1998) · PubMed · Cited by 38
Impact of Clozapine Prescription on Inpatient Resource Utilization
SERNYAK, M. J., ROSENHECK, R., DESAI, R., STOLAR, M., & RIPPER, G. (2001) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-200111000-00006 · Cited by 36 · cited 1×
“Suicide occurred at similarly low rates with both treatments, and was not altered during treatment with clozapine in this [38] or an earlier study [39].”
ResultBerk, M., Tiller, J. W. G., Zhao, J., Yatham, L. N., Malhi, G. S., & Weiller, E. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08827 · Cited by 34 · cited 1×
“Post hoc analysis of data pooled from two randomized, controlled trials of asenapine in major depressive disorders with hypomanic features supported its superiority over the placebo against both depressive and hypomanic symptoms, but did not address suicidal risk specifically [86].”
MethodThe Bipolar Book: History, Neurobiology, and Treatment
(2015) · Oxford University Press eBooks · doi:10.1093/med/9780199300532.001.0001 · Cited by 34
Psychiatric admissions and hospitalization costs in bipolar disorder in Sweden
Ösby, U., Tiainen, A., Backlund, L., Edman, G., Adler, M., Hällgren, J., Sennfält, K., van Baardewijk, M., & Sparén, P. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.09.011 · Cited by 33
Antisuicide Properties of Psychotropic Drugs: A Critical Review
Ernst, C. L., & Goldberg, J. F. (2004) · Harvard Review of Psychiatry · doi:10.1080/10673220490425924 · Cited by 32
Do Antipsychotic Drugs Influence Suicidal Behavior in Schizophrenia?
Aguilar, E. J., Siris, S. G., Siris, P. A. S. G., & MD (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4116 · Cited by 32 · cited 2×
“In addition, restless agitation (akathisia) is routinely encountered with older antipsychotics, but also with modern atypical agents, and may contribute to the risk of agitated and potentially violent or suicidal behavior [12,20,21].”
BackgroundEvaluating depressive symptoms in mania: a naturalistic study of patients with bipolar disorder
Young, A., & Eberhard, J. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s82532 · Cited by 27 · cited 2×
“However, a review of clinical observations in a total of 20,489 psychotic disorder patients found rates of suicidal events associated with aripiprazole [22] to be somewhat lower than with quetiapine [33] or ziprasidone (49 per 1000 person-years), with a not significantly different overall rate of such events compared…”
BackgroundResultTanyerı, P., Büyükokuroğlu, M. E., Mutlu, O., Ulak, G., Akar, F., Celikyurt, I. K., & Erden, F. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.09.014 · Cited by 26
[Suicidal ideations and suicide attempts after starting on aripiprazole, a new antipsychotic drug].
Scholten, M. R. M., & Selten, J. (2005) · PubMed · Cited by 24
Epidemiologic study of aripiprazole use and the incidence of suicide events
Ulcickas Yood, M., DeLorenze, G., Quesenberry, C. P., Tsai, A., Phillips, S., Willey, V. J., Niemcryk, S. J., Wells, K., Skovron, M. L., Cziraky, M. J., et al. (2010) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2047 · Cited by 22
Weisler, R. H., Khan, A., Trivedi, M. H., Yang, H., Eudicone, J. M., Pikalov, A., Tran, Q. V., Berman, R. M., & Carlson, B. X. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05495gre · Cited by 19 · cited 1×
“2011 [89] 737 MDD Pooled RCTs Placebo Suicidal ideation —— Ariprazole effective Ringbäck-Weitoft et al.”
BackgroundAsenapine versus placebo for schizophrenia
Hay, A., Byers, A., Sereno, M., Basra, M. K., & Dutta, S. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011458.pub2 · Cited by 19
Asenapine for bipolar disorder
Sajatovic, M., Scheidemantel, T., Korobkova, I., & Rej, S. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s78043 · Cited by 19 · cited 1×
“This atypical antipsychotic has regulatory approval for short-term treatment of schizophrenia and for manic or mixed episodes in bipolar I disorder [84,85].”
BackgroundAdverse Psychic Reactions to Psychotropic Drugs - A Report from the AMÜP Study
Grohmann, R., Ströbel, C., Rüther, E., Dirschedl, P., Helmchen, H., Hippius, H., Müller-Oerlinghausen, B., Schmidt, L., & Wolf, B. (1993) · Pharmacopsychiatry · doi:10.1055/s-2007-1014348 · Cited by 18
The importance of depressive mixed states in suicidal behaviour.
Rihmer, A., Gonda, X., Balázs, J., & Faludi, G. (2008) · PubMed · Cited by 16
Suicide risk and antipsychotic side effects in schizophrenia: nested case-control study
Reutfors, J., Clapham, E., Bahmanyar, S., Brandt, L., Jönsson, E. G., Ekbom, A., Bodén, R., & Ösby, U. (2016) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2536 · Cited by 16 · cited 1×
“Suicide is a major cause of death among patients diagnosed with schizophrenia, accounting for 5%–13% of deaths [8,9].”
BackgroundTandon, R. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000084034.22282.78 · Cited by 15 · cited 1×
“An exception is clozapine, a highly effective though potentially toxic antipsychotic drug with established antisuicidal effects in psychotic disorder patients and some preliminary suggestions of such benefits in mood disorder patients as well [12,38,41,90,91].”
BackgroundTreatment of depressive mood in schizophrenia with the atypical antipsychotic quetiapine
Khouzam, H. R. (2000) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(2000)11:2<80::aid-da5>3.0.co;2-7 · Cited by 15
Holzer, L., & Eap, C. B. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000185024.33032.86 · Cited by 14 · cited 1×
“However, aripiprazole has also been associated with excessive arousal, anxiety, and akathisia, which might increase suicidal risk, as has been suggested in case reports [82,83].”
BackgroundOquendo, M. A., Feldman, S., Silverman, E., Currier, D., Brown, G. K., Chen, D., Chiapella, A. P., Fischbach, R. L., Gould, M. S., Stanley, B., et al. (2011) · Archives of Suicide Research · doi:10.1080/13811118.2011.541146 · Cited by 14 · cited 1×
“Useful information may be forthcoming as more therapeutic trials include explicit assessments of suicidal behaviors rather than relying on potentially misleading ratings of suicidal risk in single items of depression rating scales or on the passive and incidental reporting of suicidal behavior as adverse events [92].”
BackgroundExtended Release Quetiapine Fumarate in Patients With Major Depressive Disorder
Weisler, R. H., Montgomery, S., Earley, W. R., Szamosi, J., & Eriksson, H. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08624 · Cited by 12 · cited 2×
“2014 [71] 1766 MDD Pooled RCTs Placebo Suicidal behavior —— No emergent suicidal behavior (drug or placebo)”
BackgroundThomas, K. L. H., Jiang, Y., & McCombs, J. S. (2015) · Annals of Clinical Psychiatry · doi:10.1177/104012371502700203 · Cited by 12 · cited 1×
“Another recent study also found that patients treated with clozapine had a significantly lower rate of suicide attempts than with olanzapine [46].”
ResultPompili, M., Rihmer, Z., Gonda, X., Serafini, G., Sher, L., & Girardi, P. (2012) · PubMed · doi:10.1708/1178.13055 · Cited by 11
Self-citationAssessments of Suicidality in Double-Blind, Placebo-Controlled Trials of Ziprasidone
Karayal, O. N., Anway, S. D., Batzar, E. D., & Vanderburg, D. G. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10m06281gre · Cited by 11 · cited 1×
“2011 [79] 5123 BD-I+II Pooled RCTs Placebo Suicidal behavior —— No emergent suicidal behavior (drug or placebo)”
BackgroundEffective Dosing and Dose Equivalency of Second-Generation Antipsychotic Medications
Buckley, P. F. (2004) · CNS Spectrums · doi:10.1017/s1092852900004375 · Cited by 9 · cited 1×
“Reported studies involving ziprasidone appear to be limited to indirect assessments related to suicidal risk, notably by documenting beneficial effects on known risk factors for suicide in persons diagnosed with schizophrenia, including anxiety, depressive symptoms, or impulsive behaviors [57,75], as well perhaps as i…”
BackgroundPompili, M., Rihmer, Z., Gonda, X., Serafini, G., Sher, L., & Girardi, P. (2012) · Rivista di psichiatria · doi:10.1708/1183.13092 · Cited by 4
Self-citation
Research works printed but not linked: 1
- Rihmer, 2008, Importance of depressive mixed states in suicidal behavior, Neuropsychopharmacol. Hung., 10, 45
Cited by
Reynolds, C. F., Jeste, D. V., Sachdev, P. S., & Blazer, D. G. (2022) · World Psychiatry · doi:10.1002/wps.20996 · Cited by 465
Bipolar depression: a major unsolved challenge
Baldessarini, R. J., Vázquez, G. H., & Tondo, L. (2020) · International Journal of Bipolar Disorders · doi:10.1186/s40345-019-0160-1 · Cited by 235
Self-citationOlanzapine versus placebo in adult outpatients with anorexia nervosa: a randomized clinical trial
Attia, E., Steinglass, J. E., Walsh, B. T., Wang, Y., Wu, P., Schreyer, C., Wildes, J., Yilmaz, Z., Guarda, A. S., Kaplan, A. S., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18101125 · Cited by 211
Prevention of suicide by clozapine in mental disorders: systematic review
Masdrakis, V. G., & Baldwin, D. S. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.12.011 · Cited by 103
“…5 meta-analyses (Hennen et al. 2005; Vermeulen et al., 2019 ; Forte et al., 2021 ); Correll et al., 2022 ; Wilkinson et al., 2022 ), and 6 review papers ( Ernst and Goldberg, 2004 ; Aguilar and Siris 2007 ; Kasckow et al., 2011 ; Pompili et al., 2016 ; Zalsman et al., 2016 ; Hawkins et al., 2021 ).”
Taipale, H., Lähteenvuo, M., Tanskanen, A., Mittendorfer-Rutz, E., & Tiihonen, J. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa111 · Cited by 85
Metadata
- Authors
- Pompili, M., Baldessarini, R., Forte, A., Erbuto, D., Serafini, G., Fiorillo, A., Amore, M., & Girardi, P.
- Affiliations
- McLean Hospital (US)
- Harvard University (US)
- Azienda Ospedaliera Sant'Andrea (IT)
- University of Genoa (IT)
- Department of Psychiatry, University of Naples SUN, Naples I-80138, Italy
- Corresponding author
- Pompili, Maurizio
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2016-10-11
- Volume
- 17
- Issue
- 10
- Pages
- 1700
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5085732
- OpenAlex
- W2530015110
- Cited by
- 78
- References
- 96
- Citations by year
- 2026: 14 · 2025: 9 · 2024: 9 · 2023: 6 · 2022: 5 · 2021: 10 · 2020: 12 · 2019: 4 · 2018: 4 · 2017: 4 · 2016: 1
- FWCI
- 0.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Funders
- Bruce J. Anderson Foundation
- Topics
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Keywords
- atypical antipsychotics, suicide risk, suicidal behavior, clozapine, olanzapine, quetiapine, ziprasidone, aripiprazole, asenapine, mood disorders, schizophrenia, suicide prevention
- MeSH terms
- Suicide Prevention, Clozapine, Humans, Risk Factors, Schizophrenia, Antipsychotic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.